A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 01 May 2017
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 08 Dec 2015 Results of matched comparison between RevLite and other two phase III trials ( MM009 and MM010) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 19 Sep 2012 Planned number of patients changed from 302 to 351.
- 08 Jun 2009 A subset analyses of pooled data from this trial and study MM009 has been published in the European Journal of Hematology, according to a Celgene media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History